Navco Pharmaceuticals (TSXV:NAV) EBIT: C$-0.05 Mil (TTM As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Navco Pharmaceuticals EBIT?

Navco Pharmaceuticals TSXV:NAV EBIT is C$-0.05 Mil as of Mar. 2023.

Navco Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2023 was C$0.01 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2023 was C$-0.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Navco Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2023 was 1,400.00%. Navco Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -18.60%.

Navco Pharmaceuticals  (TSXV:NAV) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Navco Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

ROC % (Q: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Mar. 2023 ))/ count )
=0.028 * ( 1 - 0% )/( (0 + 0.004)/ 2 )
=0.028/0.002
=1,400.00 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.094 - 0.098 - ( 0 - max(0, 0.098 - 0.094+0))
=0

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.095 - 0.091 - ( 0 - max(0, 0.091 - 0.095+0))
=0.004

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Navco Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Mar. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.028/( ( (0 + max(-0.097, 0)) + (0 + max(-0.091, 0)) )/ 2 )
=0.028/( ( 0 + 0 )/ 2 )
=0.028/0
= %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.001) - (0.098 + 0 + 0)
=-0.097

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.091 + 0 + 0)
=-0.091

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Navco Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2023 )
=-0.053/0.285
=-18.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navco Pharmaceuticals EBIT Related Terms

Navco Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for Navco Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navco Pharmaceuticals EBIT Chart

Navco Pharmaceuticals Annual Data
Trend Jun18 Jun19 Jun20 Jun21
EBIT
0.00 -0.19 -0.05 -0.08

Navco Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.05 -0.00 -0.01 0.01

TSXV:NAV vs ZTS, VTRS, NBIX: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Navco Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Navco Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Navco Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Navco Pharmaceuticals's EV-to-EBIT falls into.


Navco Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of C$-0.05 Mil mean?
Navco Pharmaceuticals (TSXV:NAV) has a EBIT of C$-0.05 Mil as of Mar. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Navco Pharmaceuticals.
Is Navco Pharmaceuticals' EBIT too high?
Navco Pharmaceuticals' current EBIT is C$-0.05 Mil.
How does Navco Pharmaceuticals' EBIT compare to ZTS and VTRS?
Navco Pharmaceuticals' EBIT of C$-0.05 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Navco Pharmaceuticals. Navco Pharmaceuticals's current EBIT is C$-0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Navco Pharmaceuticals stock overvalued right now?
Navco Pharmaceuticals (TSXV:NAV) has a current EBIT of C$-0.05 Mil. The current EBIT is C$-0.05 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Navco Pharmaceuticals (TSXV:NAV), the current EBIT is C$-0.05 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Navco Pharmaceuticals Business Description

Address 1055 West Georgia Street, Suite 1500, Vancouver, BC, CAN, V6E 4N7
Navco Pharmaceuticals Inc is engaged in creating nanotechnology products using computer algorithms. The products are used in various industries like medicine, textiles, chemicals, and additives to combat microorganisms such as viruses and bacteria. Its products include aerosol sprays, hand cleansers, hand creams, and nano BioGuard(tm)-Silver.